Neuroendocrine Carcinoma
📧 Sign up to get email alerts when something new happens for Neuroendocrine Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-08-06Clinical Trial Update: 68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs) [NA]
A completed clinical trial evaluating Gallium-68 DOTATATE PET-CT for diagnosing neuroendocrine tumors (NETs).
-
CLINICAL_TRIALS research · 2025-07-23Clinical Trial Update: Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas [Phase 2]
Phase 2 neoadjuvant chemotherapy trial in patients with localized digestive neuroendocrine carcinomas, currently recruiting, assessing disea…
-
CLINICAL_TRIALS research · 2025-07-22Clinical Trial Update: NALIRIFOX as Second-Line Chemotherapy in Extrapulmonary High-grade Neuroendocrine Neoplasms: a Prospective, Single-center, Single-arm Trial [Phase 2]
Phase 2 clinical trial evaluating NALIRIFOX as second-line chemotherapy for extrapulmonary high-grade neuroendocrine neoplasms; the study is…
-
CLINICAL_TRIALS research · 2025-06-11Clinical Trial Update: A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma [Phase 4]
This clinical trial update describes a Phase 4 study of liposomal irinotecan for advanced neuroendocrine carcinoma that is not yet recruitin…
-
CLINICAL_TRIALS research · 2025-04-03Clinical Trial Update: Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)
This clinical trial update describes the REBORN study, which aims to identify biomarkers for diagnosing neuroendocrine tumors and assessing …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-03-14Clinical Trial Update: Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE) [Phase 2]
A Phase 2 clinical trial is evaluating a triple combination of sintilimab, IBI310, and surufatinib for high-grade neuroendocrine tumors and …
-
CLINICAL_TRIALS research · 2025-03-06Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer [Phase 1]
Phase 1 study evaluating adding BAY 1895344 to standard chemotherapy for advanced solid tumors, focusing on small cell lung cancer, poorly d…
-
CLINICAL_TRIALS research · 2025-02-19Clinical Trial Update: Clinical Application of the J-PET Scanner Prototype
Clinical trial update announcing recruitment for a prototype J-PET scanner. The study targets imaging in prostate cancer, benign prostatic h…
-
CLINICAL_TRIALS research · 2025-02-10Clinical Trial Update: Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS) [Phase 2]
TAURUS is a Phase 2 clinical trial evaluating tarlatamab for advanced extrapulmonary small cell carcinoma and neuroendocrine carcinoma, with…
-
CLINICAL_TRIALS research · 2024-12-16Clinical Trial Update: Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma. [Phase 1, Phase 2]
A dose-escalation and expansion Phase 1/2 trial of ZG006 in neuroendocrine carcinoma and advanced small cell lung cancer is currently recrui…
-
CLINICAL_TRIALS research · 2024-10-15Clinical Trial Update: An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours [Phase 2]
Open-label Phase 2 registry study evaluating Lu-DOTA-TATE in patients with somatostatin receptor–positive neuroendocrine tumors.
-
CLINICAL_TRIALS research · 2024-08-13Clinical Trial Update: A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3 [Phase 2]
Phase 2 trial evaluating cabozantinib in adults with advanced, low-proliferative neuroendocrine neoplasms (NET G3), including neuroendocrine…
-
CLINICAL_TRIALS research · 2024-06-14Clinical Trial Update: Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma. [Phase 1, Phase 2]
Phase 1/Phase 2 clinical trial evaluating ZG005 in combination with etoposide and cisplatin for advanced neuroendocrine carcinoma. The study…
-
CLINICAL_TRIALS research · 2024-05-14Clinical Trial Update: Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients [Phase 2]
A Phase 2 clinical trial evaluating simultaneous hyperpolarized [1-13C]pyruvate and 18F-FDG PET/MRS in cancer patients is currently enrollin…
-
CLINICAL_TRIALS research · 2024-05-06Clinical Trial Update: Definition of a Multiparametric Prognostic and Predictive System of Classification of NET G3 Patients
Clinical trial update on a multiparametric prognostic and predictive system to classify patients with neuroendocrine neoplasms grade 3 (NET …
-
CLINICAL_TRIALS research · 2024-05-06Clinical Trial Update: PrognostIc and Predictive Factors in Unresectable Locally Advanced NEC and MANEC
This clinical trial update investigates prognostic and predictive factors in unresectable locally advanced neuroendocrine carcinoma (NEC) an…
-
CLINICAL_TRIALS research · 2017-06-01Clinical Trial Update: Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma [Phase 2]
A Phase 2 clinical trial update evaluating the FOLFIRI chemotherapy regimen as second-line treatment for Neuroendocrine Carcinoma.
-
CLINICAL_TRIALS research · 2016-11-22Clinical Trial Update: Phase I Trial: 68Ga-NODAGA-E(c[RGDyK])2 Positron Emission Tomography for Imaging Angiogenesis in Primary and Metastatic Tumor Lesions in Humans [Phase 1]
Phase I imaging trial evaluating 68Ga-NODAGA-E(cRGDyK)2 PET for assessing angiogenesis in primary and metastatic tumors; trial status is unk…